Research Institute At Nationwide Children's Hospital v. Illumina Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: The Research Institute at Nationwide Children's Hospital (Ohio)
  • Defendant: Illumina, Inc. (Delaware)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
• Case Identification: 1:25-cv-00683, D. Del., 06/03/2025
• Venue Allegations: Venue is alleged to be proper in the District of Delaware because Defendant Illumina, Inc. is a Delaware corporation and therefore resides in the district.
• Core Dispute: Plaintiff alleges that Defendant's DRAGEN™ Bio-IT software platform for genetic sequence analysis infringes a patent related to methods for improving the computational efficiency of analyzing such data in parallel.
• Technical Context: The lawsuit concerns the field of bioinformatics for next-generation sequencing (NGS), where efficiently processing massive volumes of genomic data is a critical bottleneck for research and clinical diagnostics.
• Key Procedural History: The complaint alleges that the U.S. Patent and Trademark Office (USPTO), during prosecution, explicitly found the invention to be an improvement to bioinformatics technology and "significantly more than an abstract idea." It also alleges that Defendant had extensive pre-suit knowledge of the patent through multiple channels, including from a prior exclusive licensee in 2018, a direct presentation from Plaintiff in 2019 after which Defendant declined a license, a formal notice letter in 2023, and citations to the patent's publication during the prosecution of Defendant's own patents.

Case Timeline

Date	Event
2012-03-16	Priority Date for U.S. Patent No. 9,552,458
2013-03-15	Application for '458 Patent filed
2013-11-21	U.S. Patent Application Publication No. 2013/0311106 published
2014-12-02	Edico (later acquired by Illumina) cites the '106 Publication during prosecution
2017-01-24	U.S. Patent No. 9,552,458 issues
2018-01-01	Illumina acquires Edico Genome, Inc. (approximate date based on "In 2018")
2018-11-13	Illumina allegedly notified of '458 Patent by prior licensee GenomeNext LLC
2019-09-10	Nationwide Children's gives presentation to Illumina regarding '458 Patent
2019-10-24	Illumina declines to license the '458 Patent
2023-11-08	Nationwide Children's sends notice letter to Illumina
2023-11-14	Illumina acknowledges receipt of notice letter
2024-02-23	Illumina responds to notice letter, asserting non-infringement and invalidity
2025-06-03	Complaint filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,552,458 - "Comprehensive Analysis Pipeline for Discovery of Human Genetic Variation"

The Invention Explained

• Problem Addressed: At the time of the invention, the exponential growth in data from next-generation sequencing (NGS) had outstripped the ability of computers to process it efficiently, creating a major "computational bottleneck" Compl. ¶22 Existing secondary analysis pipelines were slow, often inaccurate, and their results were not always reproducible ("non-deterministic") Compl. ¶21 A specific challenge in parallelizing the analysis was how to handle "paired-end reads" where the two ends of a DNA fragment mapped to different computational subsets (e.g., different chromosomes), as prior methods often discarded these reads, leading to a loss of accuracy Compl. ¶¶28-29 '458 Patent, col. 17:37-18:6
• The Patented Solution: The patent describes a method to improve the utilization of a computing system by parallelizing the analysis of genetic data. The method involves splitting the raw sequence data into a plurality of subsets, where each subset corresponds to a specific chromosome or the mitochondrial DNA Compl. ¶9 Crucially, the method also defines an "inter-subset" specifically for read pairs that map to different subsets (e.g., inter-chromosomal reads) Compl. ¶9 By creating separate processing paths for the chromosomal subsets and the inter-subset, the system can analyze the data in parallel without discarding the reads that cross subset boundaries, thus preserving data integrity and improving speed and accuracy Compl. ¶30 '458 Patent, col. 9:55-10:24 The patent's Figure 2A illustrates this parallel workflow, showing data being split by chromosome ("chr") and a separate path for "inter-chr.bam" files '458 Patent, Fig. 2A
• Technical Importance: This approach enabled a deterministic, scalable, and significantly faster method for secondary analysis of whole-genome data, reducing processing time from days or weeks to hours, which was a critical step for making large-scale genomic analysis practical for clinical applications Compl. ¶36 '458 Patent, col. 19:41-49

Key Claims at a Glance

• The complaint asserts independent method claim 1 and dependent claims 2-4 and 6 Compl. ¶50
• The essential elements of independent claim 1 are:
  • receiving, by the computer system, the genetic sequence data associated with the subject, the genetic sequence data specifying a plurality of chromosomes and mitochondrial DNA;
  • splitting the genetic sequence data into a plurality of subsets, each subset corresponding to either one chromosome of the plurality of chromosomes or the mitochondria DNA;
  • defining an inter-subset of the genetic sequence data for read pairs with both mates mapped to different subsets of the plurality of subsets; and
  • analyzing the obtained genetic sequence data by the computer system by dividing one or more processing steps in the analysis among a plurality of parallel processing paths, each parallel processing path corresponding to a subset of the plurality of subsets, each parallel processing path corresponding to either a chromosome of the plurality of chromosomes or the mitochondrial DNA.
• The complaint reserves the right to assert infringement of other claims of the '458 Patent Compl. ¶51

III. The Accused Instrumentality

Product Identification

The accused instrumentality is Illumina's DRAGEN™ Bio-IT software, a software suite for the analysis of sequencing data Compl. ¶41

Functionality and Market Context

• DRAGEN is a software suite used to perform secondary data analysis for applications such as urgent clinical care, enabling rapid identification of genetic variants Compl. ¶43 It accepts common genomic data formats like FASTQ and BAM/CRAM as inputs Compl. ¶44
• The complaint alleges that DRAGEN's architecture uses a "plurality of parallel processing paths which correspond to the number of processor cores" to analyze chromosomal and mitochondrial DNA, thereby reducing analysis time Compl. ¶46 This functionality can be deployed on-instrument, on-premises, or in cloud-based infrastructures Compl. ¶41
• The complaint highlights DRAGEN's use by third-party clinical diagnostics companies to process large volumes of data, suggesting its commercial importance in the genomics field Compl. ¶47 A screenshot from the '458 patent's specification shows the performance gains of the inventors' "Churchill" system, which the complaint alleges embodies the invention, over competing approaches Compl. ¶32 This figure shows Churchill completing a genetic analysis in under 10 hours, compared to 20 hours for HugeSeq and 35 hours for GATK-Queue Compl. ¶32 Compl. p. 10, Fig. 9

IV. Analysis of Infringement Allegations

'458 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
receiving, by the computer system, the genetic sequence data associated with the subject, the genetic sequence data specifying a plurality of chromosomes and mitochondrial DNA;	DRAGEN receives and processes genetic sequence data from a human subject, contained in formats such as FASTQ, BAM, and CRAM files, which include chromosomal and mitochondrial DNA.	¶44; ¶45	col. 19:35-20:6
splitting the genetic sequence data into a plurality of subsets, each subset corresponding to either one chromosome of the plurality of chromosomes or the mitochondria DNA;	DRAGEN is alleged to implement multi-threaded parallelism by breaking the genome into subsets for processing, which the complaint asserts includes splitting the data by chromosome.	¶45; ¶¶29-30	col. 10:28-34
defining an inter-subset of the genetic sequence data for read pairs with both mates mapped to different subsets of the plurality of subsets; and	DRAGEN is alleged to overcome the deficiencies of prior art systems by defining and processing an inter-subset for reads that span different chromosomes, enabling them to be tracked and processed in parallel.	¶30	col. 10:35-39
analyzing the obtained genetic sequence data by the computer system by dividing one or more processing steps in the analysis among a plurality of parallel processing paths...	DRAGEN allegedly uses a plurality of parallel processing paths corresponding to the number of processor cores on the system to analyze chromosomal and mitochondrial DNA in parallel.	¶46	col. 10:52-56

• Identified Points of Contention:
  • Scope Questions: A central dispute may be whether the term "splitting the genetic sequence data into a plurality of subsets, each subset corresponding to either one chromosome..." reads on the specific method of data parallelization used by the DRAGEN software. The defense may argue that its method of creating parallel jobs, potentially based on different criteria (e.g., equal file sizes, as contemplated in the '458 patent's specification for other embodiments but not recited in claim 1), does not meet this specific claim limitation.
  • Technical Questions: The analysis will likely focus on the "defining an inter-subset" element. The complaint alleges DRAGEN performs this step but relies heavily on high-level descriptions and comparisons to prior art. Plaintiff will need to provide evidence showing that DRAGEN's software architecture specifically creates and processes a distinct data category for inter-chromosomal read pairs, as opposed to handling such reads through a more general parallel processing or data management technique that does not meet the claim's definition of an "inter-subset."

V. Key Claim Terms for Construction

• The Term: "defining an inter-subset of the genetic sequence data for read pairs with both mates mapped to different subsets"
• Context and Importance: This term appears to be the core novel concept intended to solve the problem of handling inter-chromosomal reads in a parallel workflow. Its construction is critical because it distinguishes the claimed method from prior art that either discarded such reads or used less efficient parallelization. The infringement analysis will depend on whether DRAGEN's method of managing reads that cross computational boundaries constitutes "defining an inter-subset" as required by the claim.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: Practitioners may argue that the general description of overcoming prior art deficiencies supports a broader meaning. The specification states the invention overcame the problem of prior art discarding "inter-chromosomal reads" by "defining an inter-subset for reads that spanned two subsets" Compl. ¶¶29-30 This could suggest any parallel processing method that successfully tracks and processes such reads, rather than discarding them, meets the limitation.
  • Evidence for a Narrower Interpretation: The patent's detailed description provides a specific example of this step: "read pairs with both mates mapped to different chromosomes are saved in a separate BAM file, identified in FIG. 2 by inter-chr.bam" '458 Patent, col. 10:35-39 Figure 2A explicitly shows a distinct "inter-chr.bam" file being created. Practitioners may argue this specific implementation-creating a separate, identifiable file for inter-subset reads-defines the required scope, potentially narrowing it to exclude systems that handle such reads without creating an analogous discrete "inter-subset" file.

VI. Other Allegations

• Indirect Infringement: The complaint alleges induced infringement under 35 U.S.C. § 271(b), asserting that Illumina supplies DRAGEN with the knowledge and intent that its users will infringe the '458 Patent Compl. ¶53 This is allegedly supported by Illumina's dissemination of "product manuals, and/or technical information" that instruct users on how to use DRAGEN's infringing functionality Compl. ¶54
• Willful Infringement: The complaint alleges willful infringement based on extensive pre-suit knowledge of the '458 Patent. The allegations include notice from a prior licensee in November 2018 Compl. ¶55, a presentation by Plaintiff to Illumina in September 2019 after which Illumina reviewed the patent and declined a license Compl. ¶56, and a formal notice letter in November 2023, which Illumina acknowledged Compl. ¶¶57-58 The complaint includes an image of Illumina's letter acknowledging receipt Compl. p. 17 Furthermore, it is alleged that Illumina had knowledge via its 2018 acquisition of Edico, which had cited the application for the '458 Patent during its own patent prosecution as early as 2014 Compl. ¶60

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of claim construction and scope: can the phrase "splitting the genetic sequence data into a plurality of subsets, each subset corresponding to either one chromosome," be interpreted to cover the specific parallelization architecture of the DRAGEN platform, or does DRAGEN employ a method of splitting data that falls outside this claimed method?
• A key evidentiary question will be one of technical implementation: does the accused DRAGEN software, in its actual operation, perform the step of "defining an inter-subset" for handling reads that span across computational boundaries in a manner that maps to the specific teachings and figures of the '458 patent, or does it use a different, non-infringing technical solution to the same problem?
• A central legal question regarding damages will be willfulness: given the extensive history of alleged pre-suit knowledge detailed in the complaint-including licensing discussions, prosecution history, and communications from a prior licensee-the court will need to determine if any infringement was willful, which could expose the defendant to enhanced damages.